128 related articles for article (PubMed ID: 37638819)
21. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Curr Opin Oncol; 2021 Sep; 33(5):395-399. PubMed ID: 34224482
[TBL] [Abstract][Full Text] [Related]
22. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
23. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
24. Hodgkin Lymphoma in Adolescent and Young Adults: Real-World Data from a Single Tertiary Cancer Center in India.
Nayak L; Jain H; Bonda A; Epari S; Laskar S; Gokarn A; Shet T; Gujral S; Khanna N; Bagal B; Punatar S; Goda J; Thorat J; Rengaraj K; Sengar M
J Adolesc Young Adult Oncol; 2021 Oct; 10(5):581-587. PubMed ID: 33090916
[No Abstract] [Full Text] [Related]
25. [IgD expression in various immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma in children].
Senchenko MA; Konovalov DM
Arkh Patol; 2024; 86(1):21-26. PubMed ID: 38319268
[TBL] [Abstract][Full Text] [Related]
26. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
27. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience.
Potre O; Pescaru M; Sima A; Ionita I; Tudor R; Borsi E; Samfireag M; Potre C
Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684063
[No Abstract] [Full Text] [Related]
29. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
Evens AM; Hong F; Gordon LI; Fisher RI; Bartlett NL; Connors JM; Gascoyne RD; Wagner H; Gospodarowicz M; Cheson BD; Stiff PJ; Advani R; Miller TP; Hoppe RT; Kahl BS; Horning SJ
Br J Haematol; 2013 Apr; 161(1):76-86. PubMed ID: 23356491
[TBL] [Abstract][Full Text] [Related]
30. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
31. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
[TBL] [Abstract][Full Text] [Related]
32. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin lymphoma--a survey of children and adolescents treated in Sweden 1985-2009.
Englund A; Hopstadius C; Enblad G; Gustafsson G; Ljungman G
Acta Oncol; 2015 Jan; 54(1):41-8. PubMed ID: 25203597
[TBL] [Abstract][Full Text] [Related]
34. Nodular lymphocyte-predominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma.
Sohani AR; Jaffe ES; Harris NL; Ferry JA; Pittaluga S; Hasserjian RP
Am J Surg Pathol; 2011 Nov; 35(11):1666-78. PubMed ID: 21997687
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
[TBL] [Abstract][Full Text] [Related]
37. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
38. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
Cao H; Yamamoto K; Yang LX; Weber R
Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
40. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]